Your session is about to expire
← Back to Search
Device
Non-Invasive Hemodynamic Monitoring for Pulmonary Embolism
N/A
Waitlist Available
Led By Richard N Channick, M.D.
Research Sponsored by University of California, Los Angeles
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Patients requiring intensive care unit (ICU) level care with a confirmed diagnosis of pulmonary embolism (PE) by computed tomography (CT) angiogram or endobronchial ultrasound (EBUS) prior to or within 4 hours of initiation of any PE therapy or intervention
Patient ≥ 18 years of age
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12-24 hours
Awards & highlights
Study Summary
This trial will test whether monitoring stroke volume with non-invasive blood pressure monitors can help manage patients with acute pulmonary embolism.
Who is the study for?
This trial is for adults over 18 in intensive care with confirmed pulmonary embolism (PE) who can sign a consent form. It's not for those under 120 cm tall, on ECMO, with BMI <20 or >35, atrial fibrillation, certain heart valve issues, scleroderma, or end-stage renal disease.Check my eligibility
What is being tested?
The study tests non-invasive blood pressure monitors to measure cardiac output and stroke volume in PE patients. It aims to see how these measurements relate to PE outcomes and change with treatment.See study design
What are the potential side effects?
Since the intervention involves non-invasive monitoring without drugs or invasive procedures, significant side effects are not expected. However, discomfort from wearing the monitor may occur.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I was diagnosed with a lung clot and needed ICU care before or soon after starting treatment.
Select...
I am 18 years old or older.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12-24 hours
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12-24 hours
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
blood pressure (BP)
cardiac index (CI)
cardiac output (CO)
+4 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: Patients diagnosed with Pulmonary EmbolismExperimental Treatment1 Intervention
Patients requiring intensive care unit (ICU) level care with a confirmed diagnosis of pulmonary embolism (PE) by computed tomography (CT) angiogram or endobronchial ultrasound (EBUS) prior to or within 4 hours of initiation of any PE therapy or intervention.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Non-invasive hemodynamic measurements
2018
N/A
~120
Find a Location
Who is running the clinical trial?
University of California, Los AngelesLead Sponsor
1,528 Previous Clinical Trials
10,276,811 Total Patients Enrolled
3 Trials studying Pulmonary Embolism
294 Patients Enrolled for Pulmonary Embolism
Richard N Channick, M.D.Principal InvestigatorUniversity of California, Los Angeles
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I was diagnosed with a lung clot and needed ICU care before or soon after starting treatment.I am 18 years old or older.I am shorter than 120 cm.You are currently using a machine to help your heart and lungs work.You are either underweight with a low BMI or significantly overweight with a high BMI.I have been diagnosed with a heart valve issue, scleroderma, or severe kidney disease.If a patient is already using a specific monitoring system, they can still join the study. If they are using a different system, the Edwards system can be added as long as the patient agrees.
Research Study Groups:
This trial has the following groups:- Group 1: Patients diagnosed with Pulmonary Embolism
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Do you have any vacancies for participation in this research?
"According to the clinicaltrials.gov resource, this study is not currently recruiting patients for participation. Initially posted on January 2nd 2023 and most recently edited October 31st 2022, it remains inactive despite 230 other trials actively seeking participants at present."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger